ConductScience.org, home

Comparison · NCT00525798-97b5b6bb

SMC021 vs Placebo: Number of Patients With Non-vertebral Fractures

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. SMC021 vs Placebo: Number of Patients With Non-vertebral Fractures. Trial comparisons, record NCT00525798-97b5b6bb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00525798-97b5b6bb

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03210.02570.0401wilson
Risk in group 20.03520.02840.0435wilson
Risk difference, group 1 minus group 2-0.00304-0.01350.00739newcombe hybrid score
Risk ratio, group 1 over group 20.9130.6711.24log
Odds ratio, group 1 over group 20.9110.6621.25log
Number needed to treat, for one fewer participant with the outcome on SMC021 than on Placebo328from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1SMC0211 tablet of 0,80 mg SMC021 daily752,334OG000
Group 2Placebo1 tablet of placebo daily822,331OG001

Outcome

Type
SECONDARY
Title
Number of Patients With Non-vertebral Fractures
Description
The secondary outcome was the occurrence or not of a non-vertebral fracture during the 3 year observation period. Non-vertebral fractures of interest were: hip fractures, forearm fractures, humurus fractures, rib fractures and clavicular fractures.~Any new non-vertebral fractures while on-study were recorded. A copy of radiographs confirming the fracture, as well as a copy of the radiologist's report was to be obtained. A copy of the emergency room discharge letter or a hospital discharge letter was also obtained.
Time frame
From baseline to month 36
Population
all randomized patients

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D
NCT number
NCT00525798
Phases
PHASE3
Conditions
Osteoporosis
Interventions
SMC021 Oral calcitonin, SMC021 Placebo
Lead sponsor
Nordic Bioscience A/S
Results first posted
2012-10-18

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00525798-97b5b6bb